217 results about "Sulfonilamide" patented technology

The invention belongs to the technical field of sulfonamide synthesis, and particularly relates to a green and environment-friendly sulfonamide amidation preparation method. Comprising the following steps: adding chlorosulfonic acid into a reactor, stirring, heating, adding o-nitrochlorobenzene, carrying out staged heat preservation, cooling, and adding thionyl chloride to obtain 2-nitro-4-chlorine sulfonate-chlorobenzene; the method comprises the following steps: separating and filtering 2-nitro-4-chlorine sulfonate-chlorobenzene, adding ammonia water, stirring, preserving heat, and carrying out filter pressing to obtain 2-nitro-4-amine sulfonate-chlorobenzene; the preparation method comprises the following steps: adding liquid caustic soda into 2-nitro-4-amine sulfonate-chlorobenzene, stirring, heating, and adjusting the pH value to obtain 2-nitro-4-amine sulfonate-phenol; the method comprises the following steps: adding water, a catalyst and hydrazine hydrate into 2-nitro-4-amine sulfonate-phenol, heating, stirring, and carrying out filter pressing to obtain 4-sulfonamide-2-amino-phenol. According to the preparation method of sulfonamide, generated tail gas is subjected to falling film absorption treatment, and the product prepared by the preparation method is high in purity.

This invention discloses an analytical method for benzothiazole contaminants, comprising the following steps: detection by high performance liquid chromatography (HPLC), with the following chromatographic conditions: a phenylhexyl column as the stationary phase, mobile phase A being water, mobile phase B being acetonitrile, and gradient elution; wherein the benzothiazole contaminants are at least one of 2-aminobenzothiazole, 2-hydroxybenzothiazole, benzothiazole, 2-methylbenzothiazole, 2-mercaptobenzothiazole, 2,5-dimethylbenzothiazole, 2-cyanobenzothiazole, ethyl 2-carboxylate benzothiazole, 2-chlorobenzothiazole, 2-bromobenzothiazole, 2-methylthiobenzothiazole, phenylthiocyanate, N-tert-butyl-2-benzothiazole sulfenamide, 2-(2-hydroxyphenyl)-benzothiazole, N-cyclohexyl-2-benzothiazole sulfinamide, dibenzothiazole disulfide, and N,N-dicyclohexyl-2-benzothiazole sulfonamide.

This invention discloses a method for preparing sulfonamide-modified benzo[a]fluorene-5-one derivatives, using 1,7-enyne and N Using sulfonylaminopyridine salts as raw materials, a series of sulfonated benzo[a]fluorene-5-one compounds were successfully synthesized by catalyzing the sulfonation / cyclization tandem reaction of 1,7-enynes under photocatalytic conditions. This method has excellent functional group tolerance and high economic applicability.

A use of a sulfonamide compound represented by formula (I) or a pharmaceutical composition comprising same in the preparation of a drug for treating pulmonary edema.

The present invention relates to a novel crystalline form of a helicase-primase inhibitor compound, and to pharmaceutical compositions comprising the novel crystalline form, to methods of production of the novel crystalline form, to the crystalline form in medicine and for use in the treatment of herpes viral infections.

Rubber compositions including sulfonamides, and golf ball cores made from such compositions are disclosed. The type and concentration of components in the composition affect the properties of cores made therefrom, including, for example, coefficient of restitution and compression, and, thus, can be used to produce golf balls having desirable performance characteristics.

Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1 / Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.

Provided herein are amorphous and crystalline hemisulfate salt forms of the formula.Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.

The compounds of formula (I) wherein the substituents are as defined in claim 1 and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of these compounds may be used as insecticides. [Formula 1] JPEG2026501744000117.jpg33161

The invention discloses an indole pyridine chalcone compound and application thereof in medicine for treating colitis, and belongs to the technical field of biological medicine. The compound has a structure as shown in a formula I, wherein R1 is selected from C1-C8 alkyl, C1-C8 alkoxy, halogen, cyano, nitryl and morpholinyl, and R2 is selected from nitryl. According to the invention, multiple excellent pharmacophores such as indole, pyridine, chalcone, sulfonamide and the like are fused in the same molecule for the first time, the preparation method does not need pre-activation of a substrate, does not need a metal catalyst or an additive, and has the advantages of mild reaction conditions, high yield, good selectivity, low cost and environmental friendliness. The compound has strong inhibitory activity on hexokinase 2 (HK2), can significantly inhibit inflammatory response and regulate macrophage polarization, shows an excellent colitis treatment effect in in-vivo and in-vitro experiments, provides a new choice for developing novel colitis treatment drugs, and has a wide medical application prospect.

The application belongs to the method for improving the energy conversion efficiency and stability of organic-inorganic hybrid perovskite solar cells, and the main content is that ethyl benzene sulfonyl lactam (PSAD) containing sulfonamide functional group is combined with-NH2 and Pb 2+ in perovskite material respectively through hydrogen bond and coordination effect to passivate the crystal defects caused by the two kinds of functional groups and cations in perovskite crystal grains. The oxygen atom of the sulfoxide group in PSAD can not only fix the organic amine ion in perovskite through hydrogen bond, but also can form Pb 2+ …O coordination bond with Pb to passivate the defects caused by Pb. The method passivates the grain boundary, reduces the non-radiation recombination of carriers, enhances the charge transport of perovskite thin film, and significantly improves the energy conversion efficiency and stability of perovskite solar cells. The additive PSAD is cheap and easy to obtain, which provides the possibility for industrialization.

The invention provides a synthesis method of a negative charge highly delocalized sulfonyl imide alkali metal salt {[(R3SO2) (R2 (R1SO2N) SO) N] M), M = Li, Na, K, Rb or Cs}. The synthesis method comprises the following steps: carrying out oxidation and fluorination reaction on alkyl (S-alkyl sulfonyl imide) potassium sulfinate (or rubidium or cesium) and an N-fluorine electrophilic reagent to synthesize alkyl (S-alkyl sulfonyl imide) sulfonyl fluoride with the yield of 70-90%; the obtained alkyl (S-alkyl sulfimide) sulfonyl fluoride and sulfamide containing substituent R3 or alkali metal salt thereof are subjected to nucleophilic substitution reaction, the product is purified to obtain the high-purity negative-charge highly-delocalized sulfimide alkali metal salt, and the method has the characteristics that the operation is simple, the raw materials are low in price, the product is easy to separate and purify, the method is suitable for industrial mass production, and the like; and the prepared negative charge highly delocalized sulfimide alkali metal salt is high in chemical stability and good in solubility, and is a preferable electrolyte material for realizing high-specific-energy power and energy storage batteries.

The invention relates to an onium salt, a photoacid generator, a chemically amplified resist composition and a pattern forming method. The present invention is an onium salt represented by general formula (A). Thereby, provided is an onium salt used in a chemically amplified resist composition having excellent lithography performance such as high sensitivity, CDU, MEEF, and LWR in optical lithography using high-energy rays. In the formula, m1 is an integer of 1-4. And m2 is 1 or 2. R1 represents an electron-withdrawing group such as a hydrogen atom, a hydrocarbon group, or a cyano group; lA and LB each represents a single bond, a carbonyl group, an ether bond, an ester bond, an amide bond, a sulfonate bond, a sulfonamide bond, a carbonate bond, a urethane bond, or a hydrocarbylene group. W1 is a hydrocarbylene group containing an alicyclic structure, and a carbon atom forming the alicyclic structure has two atomic bonds. And W2 is a hydrocarbon group containing an alicyclic structure. Z + is an onium cation.

Telomerase inhibitor compounds are provided. Some compounds contain a lactone or lactam group covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In other examples, a sulfonamide-containing moiety is covalently bonded to a phenyl ring, which is itself bonded to a pyrazole group. In some embodiments, the telomerase inhibitor compounds have an amide moiety and a vinyl sulfonamide group bonded to an aromatic group. In other examples, the inhibitor compounds have an isothiazolidine 1,1-dioxide core bonded to a phenyl group. Aspects of the present invention also include pharmaceutical compositions containing the telomerase inhibitor compounds of the present invention, as well as methods for treating telomerase-related diseases or conditions.

The application discloses a preparation method of a trans-7H-pyrrolo[2,3-d]pyrimidine compound, and the full name of the trans-7H-pyrrolo[2,3-d]pyrimidine compound is trans-N-methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexylmethanesulfonamide maleate, which is prepared from trans-4-[(tert-butoxycarbonyl)amino]cyclohexane carboxylic acid and 4-chloro-7H-pyrrolo[2,3-d]pyrimidine as starting materials through reduction, chlorination, substitution, oxidation, methylation, condensation and salt formation reactions. The preparation method has the advantages of few reaction steps, simple operation, low production cost, high production efficiency, high yield, high product purity and suitability for scale-up production.

To provide a solid electrolyte capable of improving ion conductivity.SOLUTION: Wherein the molecular crystal includes a sulfolane-based compound and 112233, - hexafluoropropane-1, 3-disulfonimide lithium (LiCFSA) as a lithium salt, and the inorganic filler is SiO2, A normalized surface area WA (1g / gSE) of the inorganic filler is 15 to m2 / gSE, where W (g / gSE) is a mass of the inorganic filler with respect to m2 of the inorganic filler, and A (900m2 / g) is a specific surface area of the inorganic filler.SELECTED DRAWING: Figure 1

The present technology relates to methods for the synthesis of a PFAS-free lithium single-ion polymer which comprises simultaneously reacting a sulfonyl chloride compound with an aromatic sulfonamide compound and a compound that is suitable to act as a quenching base. The simultaneous reaction of sulfonyl chloride with the aromatic sulfonamide compound and the compound that is suitable to act as a quenching base yields the single-ion monomer.

The present invention provides solid forms of (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide, salts and solvates thereof, as well as therapeutic uses thereof and pharmaceutical compostion comprising them.

The application relates to the technical field of aspirin pharmaceutical chemistry, in particular to an aspirin-sulfonamide hybrid, a preparation method and application thereof. The preparation method can synthesize a plurality of novel aspirin-sulfonamide hybrids by taking piperazine as a bridge, and by a three-step continuous method of "acyl chlorination, sulfonamidation and N-acylation" according to a "molecular hybridization principle". In the process, only one separation and purification is performed, and the preparation steps are simple. The aspirin-sulfonamide hybrid prepared by the method is most effective on human non-small cell lung cancer cells A549, and the activity is more than 33 times higher than that of a parent aspirin, and is similar to the activity of an anticancer drug irinotecan. The aspirin-sulfonamide hybrid 3k prepared by the method has a certain inhibitory effect on various cancer cells. The hybrid can induce human non-small cell lung cancer A549 cell apoptosis in a concentration-dependent manner, and can induce human non-small cell lung cancer A549 cell cycle arrest in the G0 / G1 phase, and inhibit cell growth.

This invention discloses a method for synthesizing monosubstituted sulfonylamidinium compounds. In an air atmosphere, using commercially available primary sulfonamides and nitriles as substrates, inexpensive trifluoromethanesulfonic anhydride as a catalyst, and trifluorotoluene as a solvent, the product can be efficiently obtained. Compared with existing technologies, this method has the following advantages: inexpensive and readily available reactants; no need for cumbersome synthesis methods; simple reaction system; high atom economy with 100% atom utilization; broad substrate range, compatible with various functional groups; and simple operation.

The invention relates to an internal sulfonamide compound and a preparation method thereof. The invention relates to a preparation method of a sulfamide compound, which comprises the following steps: mixing an aminomalonic acid diethyl ester compound or an N-benzyl malonic acid monomethyl ester monoamide compound, a beta-aryl vinyl sulfonyl fluoride compound and MS, adding a solvent and a base catalyst, reacting at room temperature for 12-24 hours, separating and purifying to obtain the amide compound. The sulfamide compound and the preparation method thereof have the advantages of being simple in method, free of transition metal catalysis, wide in substrate range, mild in reaction condition, good in universality and the like.

The present invention is directed to compound(s) and methods for use thereof, such as for the treatment and prevention of a disease / disorders related with FTO activity in a subject.

The invention discloses a bentazone intermediate sulfonation-chlorination two-step continuous preparation process which comprises the following steps: continuously metering and adding a solvent, chlorosulfonic acid, triethylamine, isopropylamine and a catalyst into a first-section tubular reactor, and carrying out sulfonation reaction to obtain a reaction material isopropylaminosulfonic acid; continuously introducing the reaction material isopropylamine sulfonic acid into a second section of tubular reactor, and simultaneously continuously metering and adding methyl anthranilate and phosphorus oxychloride for chlorination reaction; after the reaction is finished, quenching the reaction liquid with water, and carrying out layering and distillation treatment to obtain an intermediate o-isopropylamine sulfonamide methyl benzoate solid; and carrying out ring-closure reaction on the intermediate o-isopropylamino sulfonamido methyl benzoate solid and sodium methoxide in a methanol solution to prepare the bentazone active compound. According to the method, the defects of low bentazone product content and poor yield caused by high temperature of intermittent sulfonation and chlorination are effectively overcome, the operation time is shortened, and the productivity is improved.

It relates to a cleansing composition, comprising at least one sulfur-containing anionic surfactant, at least one betaine-derive amphoteric surfactant from sultains, at least a-hydroxy acid, at least one β-hydroxy acid; and at least one organic basifying agent selected from alkanolamines.

The application belongs to the technical field of biomedicine, and particularly relates to a benzene sulfonamide derivative and application thereof in antidepressant drugs. The structural general formula of the compound is (I). The compound or a pharmaceutically acceptable salt thereof has agonistic activity on 5-hydroxytryptamine 2A type receptors. The compound is determined to have good antidepressant activity through a mouse tail suspension test model, an open field test model and a forced swimming test model, is a novel antidepressant compound with wide application prospect, has no hallucinogenic effect, and can be developed into an antidepressant therapeutic drug.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

A method for preparing N-phenyl-N-trichloromethylthio phenyl sulfonamide by one-pot method, organic solvent, aniline and catalyst are added to phenylsulfonyl chloride, then slow addition of acid binding agent, incubation for 1-4 h to obtain a reaction solution containing intermediate N-phenyl phenyl sulfonamide; the system is cooled to 0-20℃, slow addition of per-chloromethylthio alcohol, after the end of feeding, continue to react for 1-4 h; then add water to separate the phases, add appropriate amount of water in the organic phase to distill the organic solvent, filter to obtain N-phenyl-N-trichloromethylthio phenyl sulfonamide. The method uses organic solvent as solvent, adopts two-step reaction one-pot method, the process is simple, improves the reaction conversion rate, effectively reduces the generation of by-products, the yield of the product is high, and the quality is good. The used organic solvent and acid binding agent can be recycled and used, which reduces the production cost and greatly reduces the three wastes, and is suitable for industrial production.

Additives that decompose during charging of alkali-metal battery and alkali-ion battery cells such that the additives form part of the SEI layer and the CEI layer are provided for adding to electrolytes in such cells. Sulfonamide-based compounds may be used as additives into baseline electrolytes for alkali metal and alkali-ion batteries. As electrolyte additives, these compounds promote the formation of inorganic-rich solid electrolyte interphases and passivates electrode interfaces, resulting in improved battery performance. Solvents for the baseline electrolyte may include carbonate-based, ether-based, ester-based, sulfone-based, sulfonated-based, nitrile-based, sulfonamide-based, phosphate-based, ionic liquids, and mixtures thereof. These solvents may be non-fluorinated or fluorinated. The percent weight of solvent with respect to the total weight of the electrolyte may be from 0.05 wt % to 99 wt %, and preferably from 10 wt % to 90 wt %.